CD28 and myeloid sarcoma: For instance, two recent studies showed that effector T cells from patients with MS may also acquire resistance to Treg cell suppressive mechanisms in an IL-6 receptor-dependent manner54,55 and CD28 stimulation of peripheral CD4+ T cells from patients with RR MS strongly upregulates IL-6 production9.